NASDAQ: CYTK · Biotechnology
Cytokinetics (CYTK) fair value and price range
As of 14 Nov 2026, Faircurve's model values Cytokinetics (CYTK) at $63.03 a share. The stock last closed at $51.65, which puts the model's fair value 22.0% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 17 Nov 2026. Cytokinetics, Incorporated.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $51.97 to $63.03 (+21.3%). The multiple the model anchors on moved, lifting the fair value: most of the move.
What the model makes of itThe price of $51.65 is 22.0% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 23 Feb 2027. Options prices imply a move of about 17% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give CYTK?
The calibrated range for CYTK over 63 trading days is $42.56 to $63.29. It sits around the last close, and its width comes from the volatility that CYTK's own options imply (59% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $36.65 to $100.36. In 58% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Cytokinetics, Incorporated (CYTK) is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Faircurve's model put the fair value of Cytokinetics at $63.03 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $51.97, so the model's fair value moved +21.3%. In the model's own words, the multiple the model anchors on moved, lifting the fair value: most of the move. The calibrated range over 63 trading days is $47.16 to $67.39. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations refreshed 14 Nov 2026. The model grades the evidence behind this valuation as low.
Cytokinetics scores 44 out of 100 on the model's overall quality score, a composite of six factors measured against comparable companies. Growth quality scores 95, with trailing revenue growth at 376.6% against a peer median of -45.6%. Profitability scores 5, with ROIC at -94.7% against a peer median of -70.9%. The model compares it with Protagonist Therapeutics, TG Therapeutics, BioMarin Pharmaceutical and Bio-Techne.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CYTK report earnings, and how has the stock reacted?
Cytokinetics's next earnings report is scheduled for 23 Feb 2027. Companies can move their dates.
Options prices on 17 Nov 2026 imply a move of about 13.4% in either direction through the nearest expiry, about 30 days out. That is the size the market is pricing, not a direction. CYTK's 30 day implied volatility works out to about 16.9% over one month.
Around its last 3 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CYTK's last 8 reports, ignoring direction, was 4.6%.
Earlier reports are left out: the options record before 5 May 2026 is not comparable.
What the options market has priced for a month's move in CYTK
How does CYTK score on business quality?
Cytokinetics's overall quality score is 44 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 5 | -94.7%ROIC | -70.9% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 63 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 95 | 376.6%Revenue growth, trailing | -45.6% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 38 | 0.0%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 70 | -1.54xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 1819.1 ptsEBITDA margin downside volatility, 5y | 35.6 pts |
How does CYTK compare with similar companies?
The companies in biotechnology closest to Cytokinetics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PTGX Protagonist Therapeutics, Inc. | $124.67 | $104.97 | -15.8% | Overvalued |
| KRYS Krystal Biotech, Inc. | $298.55 | $352.42 | +18.0% | Low evidence grade |
| ARWR Arrowhead Pharmaceuticals, Inc. | $42.99 | $53.67 | +24.8% | Low evidence grade |
| TGTX TG Therapeutics, Inc. | $62.71 | $75.36 | +20.2% | Undervalued |
| LGND Ligand Pharmaceuticals Incorporated | $293.81 | $282.99 | -3.7% | Low evidence grade |
| BMRN BioMarin Pharmaceutical Inc. | $58.51 | $69.09 | +18.1% | Undervalued |
| HALO Halozyme Therapeutics, Inc. | $95.97 | $111.93 | +16.6% | Low evidence grade |
| TECH Bio-Techne Corporation | $72.63 | $65.76 | -9.5% | Fairly valued |
What the comparable companies' multiples alone would give for CYTK, the peer-implied price, is $386.18 a share on this run. The fair value weighs that against the company's own multiple.
Cytokinetics at a glance
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
- Market value
- $7.8B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $408M
- Consensus revenue growth, next fiscal year
- +83.9%
- Analysts with estimates
- 16
- Beta to the US market
- 0.93
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Cytokinetics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for CYTK was $51.97. As of 14 Nov 2026 it is $63.03, a change of +21.3%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Cytokinetics's valuation
Is Cytokinetics stock undervalued or overvalued?
Faircurve's model puts CYTK's fair value at $63.03 a share against a last close of $51.65, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is CYTK's fair value?
$63.03 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $36.65 to $100.36.
What price range does the model give CYTK?
$42.56 to $63.29 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Cytokinetics report earnings next?
The next report is scheduled for 23 Feb 2027. Companies can move their dates.
How much has CYTK moved on past earnings reports?
Across its last 8 reports the median two session move was 4.6%, ignoring direction. The largest was +13.3% around the report of 5 May 2026.
How confident is the model in this valuation?
The model's evidence grade for CYTK is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CYTK
The model holds no idea open on CYTK today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CYTK with their outcomes. A free account is enough.